DNL.L (Mkap €25 M) Attraktive Medikamente vor der Zulassung (Seite 78)
eröffnet am 15.07.19 22:09:04 von
neuester Beitrag 15.11.22 13:24:57 von
neuester Beitrag 15.11.22 13:24:57 von
Beiträge: 969
ID: 1.307.455
ID: 1.307.455
Aufrufe heute: 3
Gesamt: 134.192
Gesamt: 134.192
Aktive User: 0
ISIN: GB00BDB6Q760 · WKN: A2ACSA
0,2820
EUR
0,00 %
0,0000 EUR
Letzter Kurs 01.11.22 Frankfurt
Neuigkeiten
Werte aus der Branche Dienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5350 | +18,36 | |
| 9,402 | +13,10 | |
| 13,640 | +9,91 | |
| 59.200,00 | +9,83 | |
| 0,5800 | +9,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,370 | -10,57 | |
| 9,6900 | -11,79 | |
| 0,5100 | -12,82 | |
| 1,5100 | -22,16 | |
| 60,01 | -23,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ich überlege ernsthaft wieder einzusteigen.
Sind in nächster Zeit fundamentale News zu erwarten?
Ist Biohero hier noch investiert?
Danke
Sind in nächster Zeit fundamentale News zu erwarten?
Ist Biohero hier noch investiert?
Danke
Antwort auf Beitrag Nr.: 61.734.214 von Forsys am 21.10.19 12:25:42Sieht aus, wie abgesprochen und rüber geschoben.
Antwort auf Beitrag Nr.: 61.706.440 von Stoxtrayder am 16.10.19 16:54:17Kurs eben kurz auf 26 Pence abgestürzt, nachdem jemand 384k abgeladen hat.
Jetzt wieder bei 32 Pence.
Jetzt wieder bei 32 Pence.
Vielen Dank für die Info 👍
Habe eben ein Update vom CFO erhalten:
Dear xxx,
In relation to your questions below:
Business update
• The Alkindi NDA submission is on track for this quarter
• The Chronocort MAA submission is on track for this quarter
• Current cash lasts until early Q3 2020
Investor relations
The Board does understand – and share – your frustrations at the share price performance. Unfortunately, there are several factors affecting small cap healthcare companies at the moment:
• Brexit – a lot of cash has been taken out of UK equities pending resolution of Brexit
• Investor base – a number of large investors who have historically supported the sector have cycled out of small cap healthcare (e.g. Invesco, Legal & General, Aviva, Fidelity) or have closed funds (e.g. City Financial).
• Woodford – as you will have read, the decline of the Woodford funds has impacted investor sentiment for healthcare stories
Nevertheless, Diurnal has been proactive with 26 institutional investor meetings in the last 4 weeks (both UK and US) as well as retail investor focused activities, with more planned. We are currently covered by three analysts – this is unlikely to increase at present as a result of the changes implemented in MIFID II making it unprofitable for banks to cover stocks where they are not the broker.
With regards to management share purchases, you will see that the Board does periodically purchase shares; however, this is only possible when the company is in an open period for trading.
I hope that this answers your questions.
Best regards
Richard Bungay
Chief Financial Officer
Dear xxx,
In relation to your questions below:
Business update
• The Alkindi NDA submission is on track for this quarter
• The Chronocort MAA submission is on track for this quarter
• Current cash lasts until early Q3 2020
Investor relations
The Board does understand – and share – your frustrations at the share price performance. Unfortunately, there are several factors affecting small cap healthcare companies at the moment:
• Brexit – a lot of cash has been taken out of UK equities pending resolution of Brexit
• Investor base – a number of large investors who have historically supported the sector have cycled out of small cap healthcare (e.g. Invesco, Legal & General, Aviva, Fidelity) or have closed funds (e.g. City Financial).
• Woodford – as you will have read, the decline of the Woodford funds has impacted investor sentiment for healthcare stories
Nevertheless, Diurnal has been proactive with 26 institutional investor meetings in the last 4 weeks (both UK and US) as well as retail investor focused activities, with more planned. We are currently covered by three analysts – this is unlikely to increase at present as a result of the changes implemented in MIFID II making it unprofitable for banks to cover stocks where they are not the broker.
With regards to management share purchases, you will see that the Board does periodically purchase shares; however, this is only possible when the company is in an open period for trading.
I hope that this answers your questions.
Best regards
Richard Bungay
Chief Financial Officer
Trading Spotlight
Antwort auf Beitrag Nr.: 61.702.561 von Badenfinke am 16.10.19 10:25:51
Noch nicht. Die Wahrscheinlichkeit liegt hoch, daß die nächsten Wochen was kommt...
Zitat von Badenfinke: Dann habe ich wohl zu früh verkauft ...
Gibt es denn News?
Noch nicht. Die Wahrscheinlichkeit liegt hoch, daß die nächsten Wochen was kommt...
Antwort auf Beitrag Nr.: 61.702.561 von Badenfinke am 16.10.19 10:25:51
Habe es dir ja gesagt 😬
Grüsse aus der Schweiz
Zubi
Habe es dir ja gesagt 😬
Grüsse aus der Schweiz
Zubi
Dann habe ich wohl zu früh verkauft ...
Gibt es denn News?
Gibt es denn News?
Und schwupps, 35 Pence 👌
Antwort auf Beitrag Nr.: 61.692.148 von Stoxtrayder am 15.10.19 09:32:042. Kurs 32 Pence mit 165k Aktien
Hoffentlich geht es so weiter 😁
Hoffentlich geht es so weiter 😁
Durchsuchen
